TO THE EDITOR
A short while ago a close family friend, aged 24 years, died a month after a technically successful allogeneic bone marrow transplant for acute lymphocytic leukaemia in a London teaching hospital.
The cause of death was fulminant adult respiratory distress syndrome apparently precipitated by toxoplasmosis. During the last 2 weeks of his life whilst on steroids he developed a low-grade fever with increasing C-Reactive Protein levels and was treated by the standard modalities of changing his Hickman line and using an escalating course of antibiotics and antifungals as per the Haematology Unit's protocol.
Toxoplasmosis was not considered in the differential diagnosis even though he was known to be seropositive and the donor seronegative.
After reviewing the literature it has become clear to me that there is some uncertainty about the treatment of toxoplasmosis in the bone marrow transplant setting. I would like to ask my clinical colleagues who specialise in the field of bone marrow transplants if they could help me with the following questions:
Is there a different clinical approach between the British and French to patients undergoing bone marrow transplants for leukaemia who are seropositive for toxoplasmosis? Why are patients in Britain who are seropositive for toxoplasmosis and who receive a bone marrow transplant not routinely given prophylaxis, as appears to be the practice in France?
1 Does seropositivity pose an increased risk to a patient who undergoes chemotherapy followed by conditioning with total body irradiation and anti-T cell monoclonal antibodies and who is then transplanted with cells from a seronegative donor? 2 What percentage of bone marrow transplant patients currently die of toxoplasmosis? Of those who die of ARDS or organ failure or of lung infections how many actually have autopsies which are then specifically examined for toxoplasmosis? 3 What is the current prevalence of seropositivity for toxoplasmosis in Britain today? The current data seems to Finally what constitutes informed consent in Britain if information about toxoplasmosis is not given to patients prior to transplantation? Are French patients who are found to be seropositive for toxoplasmosis informed of the possible consequences? Can a parent or a patient be expected to give informed consent to a specific plan of treatment if they do not know the risks they are about to face?
I would welcome hearing from the scientific community as to whether they consider that toxoplasmosis poses a different threat in different countries of Western Europe and whether they believe that there is a difference in clinical approach between the French and the British in the management of those leukaemia patients who are seropositive for toxoplasmosis and who undergo bone marrow transplantation.
AI Miles Seton Hall University School of Graduate Medical Education
South Orange, NJ 07079-2689, USA antigens (Ly+AML), particularly in the subtype M2 with chromosomal translocation t(8;21), 2 and in biphenotypic leukemias (BAL). 1 Data from the literature show that the coexpression of CD2 + /CD19 + can be found in both leukemic cells from patients with ALL and on normal lymphocyte precursors cells at discrete stage of maturation. 3 There are very few reports in the literature of simultaneous expression of B and T cell antigens in T-ALL. Therefore, we would like to present a case in which T lymphoblasts showed cross-lineage CD19 expression. A 63-year-old male was referred for evaluation of weight loss of 5.0 kg over the past 2 months, progressive fatigue, bilateral pleural effusion, and hepatosplenomegaly without lymphadenopathy. The white cell count was 11.6 × 10 9 /l with 80% blasts, hemoglobin was
